Gilead acquires CymaBay and with it seladelpar for the treatment of primary biliary cholangitis.

Johnson & Johnson1 announced that it has successfully completed the acquisition of Yellow Jersey, a demerged subsidiary of Numab Therapeutics to secure the global rights to NM 26, a novel, investigational first-in-class bispecific antibody, in an all-cash transaction of approximately $1.25 billion, as announced on May 28, 2024. NM26, which is ready to enter Phase II studies in atopic dermatitis (AD), targets two clinically proven pathways, IL-4R alpha subunit (IL-4R?) and IL-31, which trigger Th2-mediated skin inflammation and skin itch, respectively.

Eli Lilly and Company and Morphic Holding, Inc. announced a definitive agreement for Lilly to acquire Morphic, a biopharmaceutical company developing oral integrin therapies for treatment of serious chronic diseases